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Recurrent chromosomal translocations involving the mixed lineage leukemia gene (MLL) give rise 
to a highly aggressive acute leukemia associated with poor clinical outcome1. The preferential 
involvement of chromatin-associated factors in MLL rearrangement belies a dependency on 
transcription control2. Despite recent progress made in targeting chromatin regulators in cancer3, 
available therapies for this well-characterized disease remain inadequate, prompting the present 
effort to qualify new targets for therapeutic intervention. Using unbiased, emerging CRISPR-Cas9 
technology to perform a genome-scale loss-of-function screen in MLL-AF4-positive acute 
leukemia, we identified ENL (eleven-nineteen leukemia) as an unrecognized dependency 
particularly indispensable for proliferation in vitro and in vivo. To explain the mechanistic role for 
ENL in leukemia pathogenesis and dynamic transcription control, we pursued a chemical genetic 
strategy utilizing targeted protein degradation. Acute ENL loss suppresses transcription initiation 
and elongation genome-wide, with pronounced effects at genes featuring disproportionate ENL 
load. Importantly, ENL-dependent leukemic growth was contingent upon an intact YEATS 
chromatin reader domain. These findings reveal a novel dependency in acute leukemia and a first 
mechanistic rational for disrupting the YEATS domain in disease.
Our group has longitudinally studied and targeted oncogenic transcription via disruption of 
chromatin-dependent signaling between oncogenic transcription factors and RNA 
polymerase (Pol) II. Previously, we collaboratively reported the function of acetyl-lysine 
binding factors, the BET bromodomain proteins (BRD2, BRD3, and BRD4), in enhancer-
mediated transcription control of oncogenic MYC in hematologic malignancies4,5, notably 
including MLL6. In MLL, aberrant chromatin structure is a hallmark feature that has been 
the focus of coordinated drug discovery efforts7–12. Despite recent progress, these 
rearrangements still portend a poor prognosis requiring immediate intervention leveraging to 
high-risk protocols1, thus motivating our effort to illuminate new cancer-specific 
dependencies in MLL.
We undertook a genome-scale CRISPR/Cas9 knockout (GeCKO13) screen in the well-
studied and MLL-AF4 rearranged human acute myeloid leukemia (AML) cell line, MV4;11 
(Fig. 1a, Extended Data Fig. 1a, and Supplementary Table 1). Changes in sgRNA abundance 
after 15 days of culturing was quantified by massively parallel DNA sequencing and 
analyzed by RIGER14, revealing several known MLL drivers (FLT3-ITD, HOXA9, and 
MEIS1) and essential genes (RPL9, GAPDH, ATP5B, and CDC23) as critical to 
proliferation1,15,16. Interestingly, sgRNAs targeting the YEATS (Yaf9, ENL, AF9, Taf14, 
Sas5) domain-containing ENL gene (also known as MLLT1) were among the most highly 
depleted, which given recent elucidation of the YEATS domain as a novel acyl-lysine reader 
module17–20, prompted further investigation. ENL has been implicated in transcription 
control as a core component of the super elongation complex (SEC)21–25, which also 
includes the positive transcription elongation factor b (P-TEFb) heterodimer (CDK9 and 
CyclinT1). ENL has also been suggested to interact directly with DOT1L21,22,23, a critical 
and selective requirement in MLL-fusion leukemia7,9,11,12, altogether supporting a rationale 
for ENL in MLL pathogenesis.
In order to validate ENL as a growth requirement, four additional sgRNAs were designed 
(Fig. 1b) and tested alongside the ENL-targeted sequence most highly depleted in the initial 
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screen (sgENL_e1). Each was confirmed to mediate on-target Cas9 activity against ENL 
(Extended Data Fig. 1b), inhibiting competitive growth of MV4;11 cells similarly to loss of 
FLT3 (Fig. 1c and Extended Data Fig. 1c, d), a bona fide target in the FLT3-ITD-positive 
cell line15. Of the 7 additional cell lines tested, each of which comparably express ENL, 
(Extended Data Fig. 1e), the SEMK2 (MLL-AF4 ALL), OCI/AML-2 (MLL-AF6 AML), 
MOLM-13 (MLL-AF9 AML), NOMO-1 (MLL-AF9 AML), and SKM-1 (MLL wild-type 
AML) cell lines were sensitive to ENL loss, while only HL-60 (MLL wild-type AML) and 
JURKAT (T-ALL) were not (Fig. 1d, e and Extended Data Fig. 1f–j). Additionally, an 
MV4;11 xenotransplantation model of disseminated leukemia in mice was sensitive to ENL 
loss, exhibiting marked reductions in disease progression and an overall survival benefit with 
CRISPR/Cas9 targeting (Fig. 1f–h). In contrast, competitive growth assays revealed that 
proliferation of lineage−, Sca1+, c-Kit+ (LSK) murine hematopoietic progenitors was 
minimally affected by Enl loss (Fig. 1i, Extended Data Fig. 2a, b), qualifying ENL for 
further consideration as a leukemia target. Interestingly, but consistent with the initial 
GeCKO screen results, loss of the highly homologous YEATS-containing protein, AF9, had 
no observable anti-proliferative effects in MV4;11 or MOLM-13 cells (Extended Data Fig. 
1l), suggesting a specific, unique requirement for ENL function in acute leukemia.
Given the previous annotation of ENL as a transcriptional activator21–25, we hypothesized 
that ENL supports the pathogenesis of acute leukemia via maintenance of dysregulated gene 
expression. To test this, we employed a novel functional genetic strategy, building upon 
phthalimide conjugation of small molecules as an approach to achieve targeted protein 
degradation26. Using FKBP12F36V as a protein tag for ENL, a hetero-bifunctional small 
molecule selectively targeting FKBP12F36V and the E3 ubiquitin ligase, CRBN, induces 
degradation of the ENL chimera. Conveniently, the previously identified F36V mutation 
produces a “hole” in the protein surface that accommodates a complementary steric “bump” 
on the ligand27, thereby avoiding targeting of FKBP12WT.
With a hemagglutinin (HA) epitope tag used for detection, ENL was expressed as amino and 
carboxy terminal FKBP12F36V fusions in MV4;11-Cas9 cells and efficiently degraded at 
nanomolar concentrations by both dTAG-7 and dTAG-13 (Fig. 2a and Extended Data Fig. 
3a–d), notably within 30 min or 1 hour, respectively (Fig. 2b and Extended Data Fig. 3e). 
This system proved amenable for use in multiple cellular systems (Extended Data Fig. 3f–h) 
and durable over multiple days following a single treatment (Extended Data Fig. 3i, j), 
particularly with dTAG-13 treatment, which led to its selection for further characterization. 
Upon selective inactivation of endogenous ENL and clonal expansion of lines bearing N- 
and C-terminal fusions (Extended Data Fig. 4a, b), expression proteomics revealed exclusive 
loss of ENL with a single 3 hour dTAG-13 exposure (Fig. 2c) while FKBP12WT is spared by 
this “bump-hole” strategy.
Administration of dTAG produced dose-responsive decreases in viability and potently 
suppressed proliferation in the absence of endogenous ENL (Fig. 2d and Extended Data Fig. 
4c–f), with undetectable effects in wild-type MV4;11 cells (Extended Data Fig. 4g, h). We 
focused subsequent analyses on the C-terminally tagged MV4;11 cell line (Cas9+, ENL-
FKBP12F36V-HA+, ENL−/−) as it featured a doubling time (31.3 hr, least-squares nonlinear 
regression, R2 = 0.956) closer to that of wild-type MV4;11 (25.8 hr, R2 = 0.994) than did the 
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N-terminally tagged line (35.0 hr, R2 = 0.995). BrdU staining revealed that growth 
impairment downstream of pharmacologic ENL degradation can be attributed to rapid 
induction of G1 arrest and an accumulation of sub-G1 cells over 72 hours (Fig. 2e and 
Extended Data Fig. 4i). Consistent with prior annotations of ENL as a transcriptional 
activator, we observed subtle loss of gene expression by cell-count normalized RNA-seq at 8 
hours, followed by global downregulation of active transcripts at 24 and 96 hours (Fig. 2f). 
We noted that several well-characterized leukemic drivers, including HOXA10, MYC, 
MYB, and MEIS1 were among the earliest and most severely downregulated transcripts, 
while the myeloid differentiation marker ITGAM (CD11b/MAC-1), was contrastingly 
upregulated (Fig. 2g). Underlying global transcriptional defects at 24 hours was a 
concomitant decrease in RNA Pol II abundance at transcription start sites (TSS) and gene 
bodies of active genes (Fig. 2h, i).
By chromatin immunoprecipitation and next-generation DNA sequencing (ChIP-seq), we 
found ENL-FKBP12F36V genomic localization (using HA-directed antibody) in MV4;11 
(Cas9+, ENL-FKBP12F36V-HA, ENL−/−) cells to be closely correlated with wild-type ENL 
in the parental MV4;11 cells (Extended Data Fig. 5a), with each factor preferentially 
enriched at TSS (Fig. 3a and Extended Data Fig. 5b, c). Enrichment also correlated with 
epigenomic localization of reported YEATS domain substrates17–20, H3K9ac, H3K18ac, and 
H3K27ac (Extended Data Fig. 5d–i). Interestingly, ranking ENL-bound loci uncovered an 
asymmetric distribution of ENL on the genome whereby a small fraction (ENL: 4.0%; ENL-
FKBP: 2.5%) of all bound sites were enriched for a disproportionate amount of total ENL 
(ENL: 51.2%; ENL-FKBP: 50.1%) (Fig. 3b, c and Extended Data Fig. 5j). Within the set of 
asymmetrically loaded targets, we identified a large number of leukemogenic genes such as 
MYC, MYB, HOXA10, and MEIS1. A similar phenomenon was observed in MOLM-13 
cells with preferential localization of ENL to promoters (Extended Data Fig. 6a), notably 
correlated to H3K27ac enrichment (Extended Data Fig. 6b; GEO ID: GSM165292028) and 
asymmetrically distributed on the genome (Extended Data Fig. 6c, d).
By integrating these gene sets with kinetic gene expression profiling following dTAG-13 
exposure, we uncovered preferential downregulation of asymmetrically enriched ENL target 
genes (Fig. 3d and Extended Data Fig. 7a–c), prompting further interrogation of class-
specific RNA Pol II dynamics at ENL target genes. By ChIP-seq with cell-count 
normalization (ChIP-Rx), we uncovered preferential loss of RNA Pol II from the gene 
bodies of asymmetrically loaded targets, but with comparatively minimal effects at their 
TSS, reflecting a pause release defect at those genes (Fig. 3e and Extended Data 7d, e). 
Given previous characterization of ENL as a member of the SEC, we reasoned these effects 
might be consequences of SEC recruitment to chromatin. To test this, we focused on the 
chromatin localization of AFF4 and CDK9, which are scaffolding and catalytic subunits of 
the SEC, respectively. Following a 6-hour treatment with dTAG-13, we uncovered an evident 
loss of AFF4 from promoters of asymmetrically, but not typically, loaded targets (Fig. 3f, h, 
i and Extended Data Fig. 7f, i), which was accompanied also by a preferential loss of CDK9 
from the promoters of those genes (Fig. 3g–i and Extended Data Fig. 7g, i). This suggested 
that ENL may contribute to recruitment of the SEC to asymmetrically loaded target genes to 
promote productive elongation. To test this, we focused on the catalytic output of CDK9 
activity (phosphorylation of Ser2 of the RNA Pol II C-terminal domain heptapeptide repeat) 
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as a marker of elongating polymerase31. Following 24 hours of dTAG-13 treatment, we 
observe diminished pSer2-RNA Pol II enrichment specifically within gene bodies of ENL 
targets with asymmetric enrichment (Fig. 3h, i and Extended Data Fig. 7h, i).
As ENL has been reported to bind directly to DOT1L21,22,23, we explored the functional 
relationship between these two factors. The rapid anti-proliferative response to ENL 
destabilization suggests a mechanism distinct from DOT1L function, as both genetic and 
chemical targeting of DOT1L is characterized by a delayed (7-10 day) effect on MLL 
growth and viability7,9. Indeed, bulk levels of H3K79me2 were minimally changed by ENL 
degradation and only modest effects on locus-specific H3K79me2 were observed at 
asymmetric ENL target genes by ChIP-seq (Extended Data Fig. 8a–c). As any changes to 
H3K79me2 occur several days after the first gene-expression changes occur following ENL 
degradation (96 hours versus 6 hours), we interpret these effects as secondary events 
attributable to the effect of ENL loss. To further dissect DOT1L-independent and DOT1L-
dependent ENL phenotypes, we leveraged the rapid kinetics afforded by the dTAG/ENL 
system, finding that cell cycle and gene expression effects following ENL degradation were 
antecedent to those induced by DOT1L inhibition (Extended Data Fig. 8d, e). Moreover, 
combination treatments for 96 hours revealed an additive effect on the suppression of MYC 
and HOXA9 transcription compared to either single agent treatment (Extended Data Fig. 8f). 
Also, while we were able to reproduce previous reports that DOT1L inhibition specifically 
downregulates MLL fusion target genes7,9, we did not uncover preferential suppression of 
published MLL-AF4 target genes following dTAG-13 treatment, and MLL-AF4 target genes 
exhibit minimal overlap with asymmetrically loaded ENL targets (Extended Data Fig. 8g–
i)10,29. Together, these data support that ENL degradation produces anti-leukemic effects on 
gene expression that occur, at least in part, through DOT1L-independent mechanisms. This 
agrees with the apparent ENL requirement in MLLWT acute leukemia (Extended Data Fig. 
1h), whereas DOT1L is selectively required in MLL-rearranged leukemia7,9.
Given the evident addiction to ENL in acute leukemia cells, we employed saturating 
CRISPR-Cas9 mutagenesis to aid in the qualification of functionally relevant protein 
domains for drug discovery efforts30. We observed strong negative selection from sgRNAs 
targeting all annotated regions of ENL, with no regions emerging as a clear outlier (Fig. 4a). 
Given the sensitivity of CRISPR-Cas9 directed at the YEATS domain, and our positive 
experience approaching acetyl-lysine recognition motifs with discovery chemistry, we 
explored whether ENL-dependent growth was contingent on YEATS domain function. 
Informed by published structure-function studies of the highly homologous AF917, we 
engineered ENL mutations predicted to either minimally or severely affect acetyl-lysine 
recognition by featuring alanine replacements at Phe47 or Tyr78, respectively (Extended 
Data Fig. 9a). As previously reported for AF9, we confirmed the ability of wild-type ENL to 
bind H3K9ac and H3K27ac, and that while this interaction was moderately affected by 
mutation of Phe47 to alanine, ENLY78A exhibited a nearly complete inability to bind acetyl-
lysine (Fig. 4b and Extended Data Fig. 9b–d). Despite equivalent expression, unaffected 
nuclear localization, and confirmed thermal stability in MV4;11-Cas9 cells (Extended Data 
Fig. 9e–h), ENLF47A and ENLY78A exhibited moderate and severe defects in the localization 
to chromatin, respectively (Fig. 4c–e). Ultimately, these findings tracked with the ability of 
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each construct to rescue loss of endogenous ENL (Fig. 4f), providing genetic validation of 
the YEATS domain as a functional, emerging therapeutic target in leukemia.
In advance of identifying direct-acting inhibitors of ENL, we present data in support of a 
facile chemical biology platform to study dynamic cellular processes. We anticipate broad 
applicability of this technology beyond the scope of this study. We use the dTAG system to 
study the “fast biology” of transcription activation and elongation, capable of disentangling 
immediate versus secondary effects, complementing if not improving genetic perturbations 
(e.g. siRNA, CRISPR). Together, these studies provide support for a DOT1L-independent 
mechanism of leukemic maintenance, in which ENL recruitment of the SEC to promoters 
contributes to transactivation of as-yet undruggable oncogenes, such as MYC, MYB, and 
HOXA10. Importantly, whereas the role of ENL as a frequent fusion partner of MLL in 
leukemia has been known1, we report wild-type ENL, and specifically its YEATS domain, 
as an unrecognized cancer-specific dependency in acute leukemia. We and others may now 
pursue the discovery of chromatin-competitive antagonists of the ENL YEATS domain, with 
mechanistic guidance, as leukemia therapy.
Extended Data
Extended Data Figure 1. 
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(a) Summary of GeCKOv2 screen results in MV4;11 cells showing the number of hits (NES 
< 0.1 and p < 0.05 in both replicates) and the percentage of hits known to be essential genes. 
Right: Top fifteen hits in essential and non-essential protein-coding genes.
(b) Immunoblot of ENL 5 days after transduction with the indicated sgRNA.
(c) Immunoblot of FLT3 5 days after transduction with the indicated sgRNA.
(d) Competition-based CRISPR-Cas9 mutagenesis in MV4;11-Cas9 cells. Percent GFP+ 
subpopulation (sgRNA-positive) after transduction with lentiviral constructs co-expressing 
GFP and an sgRNA indicated. Mean ± s.d., n = 3.
(e) ENL protein expression by immunoblot of all cell lines tested for ENL-dependent 
growth.
(f–j) Same as in (d) for the cell lines and sgRNAs indicated.
(k) Indel quantification by TIDE (tracking of indels by sequence trace decomposition) 
analysis 5 days after transduction with the sgRNA indicated in MV4;11-Cas9 cells.
(l) Same as in (d) for the cell lines and sgRNAs indicated, n = 4 for MV4;11, n = 3 for 
MOLM-13.
Extended Data Figure 2. 
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(a) Validation of sgRNA targeting mouse Enl. Indel quantification of genomic Enl locus in 
NIH/3T3-Cas9 cells by TIDE (tracking of indels by sequence trace decomposition) analysis 
5 days after transduction with control sgRosa26 (left) or sgEnl (right).
(b) Mac-1and Gr-1 myeloid marker staining of viable dox-inducible Cas9-expressing LSK 
cells 9 days post-transduction with the sgRNA indicated.
Extended Data Figure 3. 
(a) Chemical structure of dTAG-7.
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(b) Dose-responsive FKBP12F36V-ENL degradation detected by immunoblot after 16 hour 
treatment of MV4;11 (Cas9+, FKBP12F36V-HA-ENL+) cells with DMSO (labelled with “− 
“) or dTAG-7 at the indicated concentration.
(c) As in (b), but with dTAG-13.
(d) Immunoblot detection of ENL-FKBP12F36V degradation in MV4;11 (Cas9+, ENL-
FKBP12F36V-HA+) after 16 hours.
(e) Kinetic evaluation of FKBP12F36V-ENL degradation by dTAG-7 (500 nM) in MV4;11 
(Cas9+, FKBP12F36V-HA-ENL+) cells.
(f) Degradation of ENL-FKBP12F36V in MOLM-13 cells following a 4-hour treatment of 
ENL-FKBP12F36V-expressing cells with dTAG-13 (500 nM).
(g) As in (f), but with NOMO-1 cells expressing ENL-FKBP12F36V.
(h) As in (f), but with JURKAT cells expressing ENL-FKBP12F36V.
(i) Long-term kinetic evaluation of ENL-FKBP12F36V degradation by a single dose of 
dTAG-7 (500 nM) in MV4;11 (Cas9+, ENL-FKBP12F36V-HA+) cells.
(j) As in (i), but with dTAG-13 (500 nM).
Extended Data Figure 4. 
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(a) CRISPR-Cas9 knockout of endogenous ENL in MV4;11 (Cas9+, ENL-FKBP12F36V-HA
+) cells. ENL/HA immunoblot in MV4;11 (Cas9+, ENL-FKBP12F36V-HA+) (P, parental) 
and MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, ENL−/−) cells.
(b) CRISPR-Cas9 knockout of endogenous ENL in MV4;11 (Cas9+, FKBP12F36V-HA-
ENL+) cells.
(c) DMSO-normalized cellular viability of MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, 
ENL−/−) cells after 72-hour treatment with dTAG-13 approximated by ATP-lite assay 
(means ± s.d., n = 4).
(d) DMSO-normalized cellular viability of MV4;11 (Cas9+, FKBP12F36V-HA-ENL+, 
ENL−/−) cells after 72-hour treatment with dTAG-7 or dTAG-13 approximated by ATP-lite 
assay (means ± s.d., n = 4).
(e) Growth over time of MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, ENL−/−) cells treated 
with DMSO or dTAG-13 (500 nM). Total number of viable cells as approximated by trypan 
blue exclusion is plotted over time (means ± s.d., n = 3).
(f–g) As in (e), but with cell line indicated at top.
(h) As in (d), but with wild-type MV4;11 cells.
(i) Representative plots of BrdU incorporation used for cell cycle analysis shown in Fig. 2f.
Extended Data Figure 5. 
(a) Correlation of ENL and ENL-FKBP12F36V genomic enrichment by ChIP-seq. Top: 
scatterplot of ENL-FKBP12F36V and ENL ChIP-seq signal (log2 rpm/bp) at the union of all 
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regions enriched with ENL-FKBP12F36V or ENL. Bottom: Venn diagram depicts the 
number of unique and overlapping regions of enrichment identified by ChIP-seq of ENL-
FKBP12F36V (18,294 total) and ENL (5,397 total).
(b) ENL binding at active enhancers. Top: Rank ordered heat map of H3K27ac, ENL-
FKBP12F36V, and ENL at H3K27ac-defined active enhancers. Rows depict a single 
enhancer (centered on an H3K27ac peak) and are sorted by ENL-FKBP12F36V signal (rpm/
bp). ChIP-seq signal (rpm/bp) is depicted by scaled color intensity. Bottom: meta plot 
representation of heat maps. Average read density is plotted against the distance from the 
enhancer center.
(c) ENL binding at promoters by ChIP-seq. Top: Rank ordered heat map of ChIP-seq signals 
at ENL-FKBP12F36V-bound promoters, sorted by ENL-FKBP12F36V levels and aligned at 
TSSs. ChIP-seq signal (rpm/bp) is depicted by scaled color intensity. Bottom: meta plot 
representation of heat maps. Average read density is plotted against the distance from the 
TSS. H3K9ac, ENL-FKBP12F36V, and ENL samples are shown also in Fig. 3a.
(d–i) Correlation of ENL and ENL-FKBP12F36V with histone acetyl-lysine residues by 
ChIP-seq. Scatterplot of ChIP-seq signals (log2 rpm/bp) at the union of all enriched regions 
for the two samples indicated in each plot.
(j) Asymmetric localization of ENL-FKBP12F36V. ChIP-seq signal (rpm) at each location is 
plotted against its rank among all occupied regions. Points colored red are loci with 
asymmetric ENL-FKBP12F36V load compared to typically loaded regions shown in gray.
P-values determined by Pearson correlation.
Extended Data Figure 6. 
(a) ENL binding at enhancers and promoters. Top: Mean H3K27ac and ENL ChIP-seq 
signal across all H3K27ac-defined active enhancers in MOLM-13 cells. Average read 
density is plotted against the distance from the enhancer center. Bottom: Mean H3K27ac and 
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ENL ChIP-seq signal at ENL-bound TSS regions in MOLM-13 cells. Average read density 
is plotted against the distance from the TSS. Dataset for H3K27ac was obtained from GEO 
ID: GSM1652920.
(b) Correlation of H3K27ac and ENL genomic enrichment by ChIP-seq. Scatterplot of 
H3K27ac and ENL ChIP-seq signal (log2 rpm/bp) at the union of all H3K27ac and ENL 
enriched regions genome-wide. P-value determined by Pearson correlation.
(c) Asymmetric localization of ENL in MOLM-13 cells. ChIP-seq signal (rpm) at each 
location is plotted against its rank among all occupied regions. Points colored red are loci 
with asymmetric ENL load compared to typically loaded regions shown in gray.
(d) Gene tracks of ChIP-seq signal (rpm/bp) at examples of asymmetrically (MYB) and 
typically enriched ENL target genes (ACTB).
Extended Data Fig 7. 
(a) Boxplot of DMSO-normalized fold changes in gene expression of typically enriched 
(gray) and asymmetrically enriched (red) ENL-FKBP12F36V target genes with dTAG-13 
(500 nM) treatment. Welch’s two-tailed t-test p-values are indicated at top.
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(b–c) Gene set enrichment analysis (GSEA) of DMSO normalized gene-expression changes 
with 8-hour dTAG-13 (500 nM) treatment compared to the set of asymmetrically loaded 
ENL (b) and ENL-FKBP12F36V (c) target genes.
(d) Boxplots of change in RNA Pol II ChIP-Rx signal (RRPM) at TSS and gene-body 
regions of typically enriched (gray) and asymmetrically enriched (red) ENL-FKBP12F36V 
target genes following 24 hour dTAG-13 (500 nM) treatment. Welch’s two-tailed t-test p-
values are indicated at top.
(e) Cumulative distribution plot of RNA Pol II traveling ratio at asymmetrically loaded ENL 
(left) and ENL-FKBP12F36V (right) target genes determined by RNA Pol II ChIP-Rx 
following 24 hour DMSO or dTAG-13 (500 nM) treatment.
(f) Left: Waterfall plot of change in AFF4 ChIP-Rx signal (RRPM) at promoters (TSS ± 5 
kb) of ENL-FKBP12F36V target genes (typically enriched in gray, asymmetrically enriched 
in red) following dTAG-13 (500 nM treatment) for 6 hours. Right: boxplot of (left) with 
Welch’s two-tailed t-test p-values indicated at top.
(g) As in (f), but for CDK9
(h) Meta-gene representations of pSer2-RNA Pol II ChIP-Rx signal at ENL and ENL-
FKBP12F36V target genes following 24 hour dTAG-13 (500 nM) treatments. TSS, 
Transcription start site; TTR, transcription termination region.
(i) Gene tracks of ChIP-seq signal (rpm/bp or RRPM/bp) at an example of an 
asymmetrically enriched ENL target gene, MEIS1.
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Extended Data Fig 8. 
(a) Immunoblot for H3K79me2 following 96 hour DMSO, dTAG-13 (500 nM), or 
EPZ-5676 (500 nM) treatment. Bottom: semi-quantitative representation of H3-normalized 
H3K79me2 signal as percent of DMSO treatment.
(b) Gene track view of H3K79me2 ChIP-seq signal (rpm/bp) at examples of ENL target 
genes (asymmetric load: MYB and MEIS1; typical load: ACTB) following 96 hour DMSO 
or dTAG13 (500 nM) treatments.
(c) Meta gene representation of H3K79me2 ChIP-seq mean read density at typically loaded 
(left) and asymmetrically loaded (right) ENL target genes.
(d) Kinetic comparison of dTAG-13 (500 nM) and EPZ-5676 (500 nM) on gene expression 
changes in MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, ENL−/−) cells. Gene expression 
quantified by qRT-PCR (ddCt method). Student’s t-tests comparing DMSO to EPZ-5676 and 
dTAG-13 are in gray and red, respectively. **** p-value < 0.0001, *** p-value < 0.001, ** 
p-value < 0.01, * p-value < 0.05, n.s. p-value > 0.05 (mean ± s.d., triplicate PCR analysis).
(e) Cell cycle analysis via propidium iodide staining of MV4;11 (Cas9+, ENL-
FKBP12F36V-HA+, ENL−/−) cells treated with DMSO, dTAG-13 (500 nM), or EPZ-5676 
(500 nM). Percentage of G1 cells were compared by two-tailed t-tests: **** p-value < 
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0.0001, *** p-value < 0.001, ** p-value < 0.01, * p-value < 0.05, n.s. p-value > 0.05 (mean 
± s.d., n = 3).
(f) Gene expression changes in MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, ENL−/−) cells 
with combination treatments of dTAG-13 (500 nM) and EPZ-5676 (500 nM). Gene 
expression quantified by qRT-PCR (ddCt method). Student’s t-test: **** p-value < 0.0001, 
*** p-value < 0.001, ** p-value < 0.01, * p-value < 0.05, n.s. p-value > 0.05 (mean ± s.d., 
triplicate PCR analysis).
(g) Overlap analysis of published MLL-AF4 target genes and asymmetrically loaded ENL or 
ENL-FKBP12 target genes.
(h) Heat map of DMSO normalized fold changes in gene expression caused by dTAG-13 
(500 nM) or EPZ-5676 (500 nM) treatment for the indicated amount of time. Raw 
expression values determined by RNA-seq were cell count normalized by spike-in of 
synthetic ERCC RNA standards. dTAG-13 data is redundant with data shown in Fig. 2g.
(i) GSEA of DMSO normalized gene-expression changes with dTAG-13 (500 nM) or 
EPZ-5676 (500 nM) treatment compared to MLL-AF4 target genes.
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Extended Data Figure 9. 
(a) Sequence alignment of AF9 and ENL YEATS domains. Identical residues are 
highlighted in gray. Two of these residues are colored red to denote sites where mutations 
were engineered into ENL for interrogation of YEATS function.
(b) Histone peptide microarray probed with lysates from 293T cells overexpressing full-
length ENL WT, F47A, or Y78A with a 3xHA epitope tag. Select residues known to be 
YEATS domain substrates and showing YEATS domain dependent signal have been boxed 
in red, blue, or orange. Several other spots showed high signal, but not enriched over the 
corresponding unmodified peptide, and not YEATS-dependent. These have not been boxed 
in.
(c) Quantification of histone peptide microarray spots containing H3K18ac or H3K27ac 
after probing with cellular lysates from 293T cells overexpressing wild-type or mutant 
3xHA-ENL. Mean ± s.d., n = 2.
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(d) Isothermal titration calorimetry (ITC) measurements showing wild type ENL bound to 
H3(4-10)K9ac in a 1:0.943 stoichiometry with binding affinity (KD) of 30.1 uM. Interaction 
was not detected with ENL Y78A.
(e) Subcellular localization of ENL. MV4;11 cells stably expressing 3xHA-ENL (wild-type, 
F47A, or Y78A) were fractionated and probed by immunoblot. Cy, cytoplasm; N, 
nucleoplasm; Ch, chromatin.
(f) Thermal stability of ENL in cells. MV4;11 cells stably expressing 3xHA-ENL (wild-
type, F47A, or Y78A) were heated to the indicated temperature to induce irreversible 
aggregation. Remaining soluble protein was isolated and probed by immunoblot.
(g) Quantification of band intensity in from (e) showing the temperature of aggregation 
(Tagg).
(h) Immunoblot to determine expression level of exogenously expressed ENL constructs 
used for rescue and ChIP-qPCR experiments.
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Figure 1. ENL is required for growth of acute leukemia
(a) RIGER analysis (normalized enrichment score, NES) of pooled CRISPR/Cas9 screen in 
MV4;11 cells. Select essential and leukemic driver genes are shown in black and blue, 
respectively.
(b) Schematic depiction of ENL domain structure: YEATS, polyproline region (P), and 
AHD (Anc1 homology domain). Numbering indicates sgRNA exon targets in (c-e).
(c–e) Competition-based CRISPR-Cas9 mutagenesis assays. GFP+ (sgRNA+) 
subpopulation percentage is depicted for the indicated day after lentiviral transduction. Mean 
± s.d., n = 3.
(f) Luminescence of MV4;11 (Cas9+, Luciferase+) cells in a disseminated model of 
leukemia at the indicated day after xenotransplantation. sgRosa denotes a control sgRNA 
targeting the mouse Rosa26 locus (non-targeting in human cells). P values obtained via two-
tailed Student’s t-tests, comparing each ENL sgRNA against the Rosa26 sgRNA. Mean ± 
s.e.m., n = 10.
(g) Representative images of mice from (f). The same mice are depicted at each time-point.
(h) Kaplan–Meier plot for overall survival of mice from (f). n = 10, p-value obtained from 
Mantel-Cox test.
(i) Competition-based CRISPR-Cas9 mutagenesis in LSK cells. Percent GFP+ (sgRNA+) 
after doxycycline induction of Cas9 expression. Mean ± s.d., n = 3.
**** p-value < 0.0001, *** p-value < 0.001, ** p-value < 0.01, * p-value < 0.05.
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Figure 2. ENL degradation induces growth arrest and transcription defects genome-wide
(a) Chemical structure of dTAG-13.
(b) Kinetic evaluation of ENL-FKBP12F36V degradation in MV4;11 (Cas9+, ENL-
FKBP12F36V-HA+) cells.
(c) Quantification of protein abundance following a 3 hour dTAG-13 treatment (500 nM) in 
MV4;11 (Cas9+, ENL-FKBP12F36V-HA+, ENL−/−) cells for proteins with 3 or more 
quantified spectral counts, n = 3.
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(d) DMSO-normalized cellular viability in MV4;11 (Cas9+, ENL-FKBP12F36V-HA+) cells 
after 72-hour treatment with dTAG-13 approximated by ATP-lite assay. Mean ± s.d., n = 4.
(e) Cell cycle analysis with DMSO or dTAG-13 (500 nM) treatment by BrdU incorporation. 
Mean ± s.d., n = 3.
(f) Heat map representation of DMSO-normalized fold changes in cell-count normalized 
gene expression values caused by dTAG-13 (500 nM).
(g) Volcano plot of data shown in (f). P-value derived from two-tailed Student’s t-test, n = 3.
(h) Meta gene representation of cell-count normalized ChIP-seq (ChIP-Rx) of RNA Pol II at 
active genes following DMSO or dTAG-13 (500 nM) treatment for 24 hours. TSS, 
Transcription start site; TTR, transcription termination region.
(i) Cumulative distribution plot of RNA Pol II traveling ratios from data shown in (h).
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Figure 3. ENL degradation attenuates SEC recruitment and activity
(a) ENL promoter localization. Top: Rank ordered heat map of H3K9ac, ENL-FKBP12F36V, 
and ENL ChIP-seq signal (rpm/bp) at ENL-FKBP12F36V-bound promoters, sorted by ENL-
FKBP12F36V signal.
(b) Asymmetric localization of ENL. ENL ChIP-seq signal (rpm) at each location is plotted 
against its rank among all ENL-occupied regions. Red depicts asymmetrically loaded loci.
(c) Gene tracks of ChIP-seq signal (rpm/bp) at examples of asymmetrically and typically 
enriched ENL target genes.
(d) Boxplot of DMSO-normalized fold change in cell-count normalized RNA-seq values 
following dTAG-13 (500 nM) treatment.
(e) Boxplots of DMSO-normalized fold change in RNA Pol II ChIP-Rx signal following 24 
hour dTAG-13 (500 nM) treatment.
(f) Waterfall plot of change in AFF4 ChIP-Rx signal at promoters (TSS ± 5 kb) of ENL 
target genes (2303 total) following dTAG-13 (500 nM) treatment for 6 hours.
(g) As in (f), but for CDK9 ChIP-Rx.
(h) Boxplots of change in ChIP-Rx signal for AFF4 and CDK9 at promoters (TSS ± 5 kb) 
and pSer2 at gene bodies of ENL target genes following dTAG-13 (500 nM) treatment (6 hr 
for AFF4 and CDK9, 24 hr for pSer2-RNAPII).
(i) Gene tracks of ChIP-Rx signal (RRPM/bp) at examples of asymmetrically and typically 
enriched ENL target genes.
P-values are indicated at top of boxplots (Welch’s two-tailed t-tests).
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Figure 4. The YEATS domain is essential for ENL-dependent leukemic growth
(a) Scanning mutagenesis of ENL by pooled CRISPR/Cas9 targeting of all exonic PAMs for 
competitive growth assays.
(b) Quantification of histone peptide microarray spots containing H3K9ac after probing with 
cellular lysates from 293T cells overexpressing wild-type or mutant 3xHA-ENL. Mean ± 
s.d., n = 2.
(c) YEATS-dependent chromatin localization of ENL. Top: gene track view of ENL-
FKBP12F36V ChIP-seq signal. Bottom: ChIP-qPCR signal at the indicated locus by 2 
independent primer pairs. Mean ± s.d., triplicate PCR analysis.
(d–e) As in (c), but for the the 5′ region of the indicated gene. Mean ± s.d., triplicate PCR 
analysis.
(f) Rescue of endogenous ENL loss by exogenous expression of wild-type and mutant ENL. 
The GFP+ (endogenous ENL-targeted sgRNA+) subpopulation percentage is depicted for 
the indicated day after lentiviral transduction. Mean ± s.e.m., n = 3.
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